Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Mevacor Pediatric Exclusivity Gets July 3 Hearing; 5 Generics Stayed

Executive Summary

The D.C. federal court is scheduled to hear arguments on Merck's Mevacor pediatric exclusivity application July 3.

You may also be interested in...

Amgen’s Challenge Over Sensipar Pediatric Exclusivity Moves To US Appeals Court

Amgen asserts FDA improperly tied pediatric exclusivity denial to lack of meaningful labeling resulting from the studies; justices question whether Amgen's data were adequate to support exclusivity but also agency's public silence on how it decides when a sponsor has 'fairly responded' to a written request.

Pediatric Studies: Must Sponsors Meet Every Detail Of US FDA Request To Get Exclusivity?

In suit against FDA, Amgen argues it provided sufficient data to obtain exclusivity for Sensipar but agency says too few patients were included in one study; court ruled against FDA in similar 2001 dispute.

FDA Quality Of Life Guidance Receives Renewed Interest After Industry Input

FDA has renewed development of a guidance on the use of quality of life claims in drug labeling and promotional materials after gathering input from industry

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts